ARQT vs RUN · rev $196.5M vs P/E 6.0, rev $2.04B
Arcutis Biotherapeutics Inc (ARQT) versus Sunrun Inc (RUN) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Latest reported ARQT revenue for 2024-12-31 was $196.5M. Net income was -$140.0M. Revenue was up 229.7% from 2023-12-31 to 2024-12-31. ARQT currently screens at market cap $1.64B.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
ARQT currently screens at market cap $1.64B. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Not investment advice. Open the ARQT and RUN stock pages for the full models.
Not investment advice.